3Best WR, Becktel -JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index: National Cooperative Crohn' s Disease Study. Gastroenterology 1976,70: 439-444.
2Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn' s disease : the ACCENT I randomised trial [J]. Lancet, 2002,359 : 1541-1549.
3Rutgeerts P,Sandborn WJ,Feagan BG,et al. Infliximab for induction and maintenance therapy for ulcerative colitis[J]. New Engl J Med,2005,353(23) :2462-2476.
4Arhur B,Miguel R. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease[J]. Inflamm Bowel Dis, 2007,13 : 1424-1429.
6Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn' s disease. N Engl J Med, 1997, 337: 1029-1035.
7D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology, 1999,116 : 1029-1034.
8Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroidrefractory ulcerative colitis: a pilot study. Inflamm Bowel Dis,2001,7:83-88.
9Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology,2005, 128:1805-1811.
10Comerford LW, Bickston SJ. Treatment of luminal and fistulizing Crohn's disease with Infliximab. Gastroenterol Clin North Am, 2004,33 : 387-406.
